Basics Heron Therapeutics, Inc. Heron Therapeutics Inc is a biotechnology company, developing products to address unmet medical needs. It is developing novel, patient-focused solutions that apply its science and technologies to already-approved pharmacological agents. IPO Date: January 23, 2014 Sector: Healthcare Industry: Biotech Market Cap: $240.2M Activated in VL: True Average Daily Range Avg Daily Range: $0.38 | 3.07% Avg Daily Range (30 D): $0.02 | 2.08% Avg Daily Range (90 D): $0.03 | 2.53% Institutional Daily Volume Avg Daily Volume: 1.24M Avg Daily Volume (30 D): 1.97M Avg Daily Volume (90 D): 1.71M Trade Size Avg Trade Size (Sh.): 159 Avg Trade Size (Sh.) (30 D): 275 Avg Trade Size (Sh.) (90 D): 288 Institutional Trades Total Inst.Trades: 3,466 Avg Inst. Trade: $1.58M Avg Inst. Trade (30 D): $.58M Avg Inst. Trade (90 D): $.76M Avg Inst. Trade Volume: .13M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.03M Avg Closing Trade (30 D): $.58M Avg Closing Trade (90 D): $.66M Avg Closing Volume: 180.22K     News Oct 29, 2025 @ 9:58 PM Heron Therapeutics Announces Appointment of Thomas... Source: Craig Collard Oct 29, 2024 @ 8:05 PM Heron Therapeutics to Report Third Quarter 2024 Fi... Source: Prnewswire Sep 17, 2024 @ 10:00 AM Chemotherapy Induced Nausea and Vomiting Treatment... Source: Fact.Mr Jul 2, 2024 @ 12:43 PM Merck (MRK) Gets Exclusive Rights to Opevesostat F... Source: Zacks Equity Research Jul 1, 2024 @ 2:31 PM FDA Rejects Rocket's (RCKT) Gene Therapy BLA for R... Source: Zacks Equity Research Financials   TTM Q3 2025 Q2 2025 Basic EPS $-.09 $-.1 $-.02 Diluted EPS $-.09 $-.1 $-.02 Revenue $ 155.1M $ 38.21M $ 37.2M Gross Profit $ 114.64M $ 26.3M $ 27.34M Net Income / Loss $ -13.58M $ -17.5M $ -2.38M Operating Income / Loss $ 1.6M $ -4.09M $ -1.64M Cost of Revenue $ 40.46M $ 11.91M $ 9.86M Net Cash Flow $ 17.33M $ 26.55M $ -2.75M PE Ratio     Splits Jan 13, 2014:   1:20 May 25, 2007:   1:4